A New Drug Trials Snapshot for STRENSIQ is now available.
STRENSIQ is a drug that treats perinatal/infantile-, and
juvenile-onset hypophosphatasia, referred to as HPP. HPP is a rare, genetic,
progressive, metabolic disease in which patients experience devastating effects
on multiple systems in the body, leading to severe disability and
Drug Trials Snapshots provide information about who participated in clinical trials
that supported the FDA approval of new drugs. The information provided in these
Snapshots also highlights whether there were any differences in the benefits and
side effects among sex, race and age groups.
See more Drug Trial Snapshots or contact us with questions at Snapshots@fda.hhs.gov.
No hay comentarios:
Publicar un comentario